Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Development and validation of a simulator-based test in transurethral resection of bladder tumours (TURBEST)

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Educational level and first-time PSA testing in general practice

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Successful extraction of sperm cells after autologous bone marrow transplant: a case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Educational level and first-time PSA testing in general practice

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objective Primary androgen deprivation therapy (ADT) remains the gold standard in the management of patients with advanced prostate cancer (PCa). ADT relieves symptoms and reduces tumor burden, but it has never been demonstrated to increase either PCa-specific or overall survival per se. Several trials have challenged this dogma. The aim of this study was to evaluate how endocrine therapy (ET) affects survival in different clinical settings of PCa. Materials and methods A review of published phase II, III and IV studies evaluating the effect of ET on survival was performed. Results In localized and locally advanced non-metastatic PCa, neoadjuvant ET before radical prostatectomy has no effect on survival. Neoadjuvant and adjuvant ET in combination with curatively intended radiotherapy results in PCa-specific and overall survival benefit, although the duration of ET remains under debate. In N + disease, the timing of ET is under debate, although data suggest that early ET is associated with decreased PCa-specific and overall mortality. In M + disease, no proper randomized trials have been performed in patients with newly diagnosed M1 disease. In metastatic castration-resistant PCa, two novel endocrine agents have been proven to increase overall survival significantly compared to placebo. Conclusions ET has never been proven to increase survival in newly diagnosed metastatic PCa in a randomized clinical trial. Nonetheless, a number of trials supports that ET with proper timing, sequencing and in combination with other therapeutic modalities increases survival in several stages of PCa.

Original languageEnglish
JournalScandinavian Journal of Urology and Nephrology
Volume50
Issue number3
Pages (from-to)135-43
Number of pages9
ISSN0036-5599
DOIs
Publication statusPublished - Jun 2016

ID: 46295562